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Abstract
The current seasonal inactivated influenza vaccine protects only
against a narrow range of virus strains as it triggers a dominant
antibody response toward the hypervariable hemagglutinin (HA)
head region. The discovery of rare broadly protective antibodies
against conserved regions in influenza virus proteins has propelled
research on distinct antigens and delivery methods to efficiently
induce broad immunity toward drifted or shifted virus strains.
Here, we report that adeno-associated virus (AAV) vectors express-
ing influenza virus HA or chimeric HA protected mice against
homologous and heterologous virus challenges. Unexpectedly,
immunization even with wild-type HA induced antibodies recog-
nizing the HA-stalk and activating FccR-dependent responses indi-
cating that AAV-vectored expression balances HA head- and HA
stalk-specific humoral responses. Immunization with AAV-HA
partially protected also ferrets against a harsh virus challenge.
Results from this study provide a rationale for further clinical
development of AAV vectors as influenza vaccine platform, which
could benefit from their approved use in human gene therapy.
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Introduction
Influenza remains a severe public health threat. The infection is
associated with high morbidity and mortality, especially in very
young or very old individuals, and has thus considerable socio-
economic impact (WHO, 2018b). Currently, influenza A viruses of
the subtypes H1N1 and H3N2 as well as the influenza B virus
lineages Victoria and Yamagata circulate in humans. Influenza
viruses are genetically and antigenically highly variable, resulting
in recurrent epidemics in humans (“flu season”). The main mech-
anism driving this variability is antigen drift caused by the accu-
mulation of point mutations in the antigenic surface glycoproteins
hemagglutinin (HA) and neuraminidase (NA). Moreover, reassort-
ment between influenza A virus subtypes can generate even
larger antigenic alterations, which may allow for a pandemic
circulation in a naı̈ve population (Palese, 2004). Influenza
pandemics occur in unpredictable intervals. In 1918, the most
devastating pandemic caused by an H1N1 virus, the “Spanish
flu,” claimed millions of deaths worldwide (Johnson & Mueller,
2002). The most recent influenza pandemic was triggered by a
related H1N1 virus in 2009, which arose from the porcine reser-
voir and imposed a high burden of disease on public health
(Fineberg, 2014).
Currently, the most effective prophylaxis against influenza is
immunization with trivalent or quadrivalent influenza vaccines,
most of which contain inactivated antigenic components of current
seasonal influenza A and B viruses. However, protection is mainly
virus strain-specific, and the efficacy against non-matched strains is
generally poor. Although a more broadly reactive live-attenuated
influenza vaccine (LAIV) is available for children, its usefulness is
limited in adults due to pre-existing immunity against previously
encountered influenza viruses (Belshe et al, 2000). The majority of
vaccine doses is produced in embryonated chicken eggs, a process
which is time-consuming and necessitates that the vaccine composi-
tion is predictively defined well in advance of the seasonal epidemic
(Gerdil, 2003). This elevates the risk for vaccine mismatch and loss
of effectiveness if the actually circulating influenza viruses represent
drift variants of the vaccine strains (Rondy et al, 2017). Seasonal
influenza vaccination also does not provide protection against
shifted or emerging zoonotic influenza A virus strains, e.g., H5N1 or
H7N9, which can be associated with increased disease severity
(WHO, 2018a). Hence, there is a generally accepted impetus for
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development of a novel broadly protective vaccine (Erbelding et al,
2018; Ortiz et al, 2018).
The seasonal vaccine predominantly induces antibodies targeting
epitopes at or surrounding the receptor binding site (RBS) within
the globular HA-head region (Caton et al, 1982). Since these
epitopes are highly variable, antibodies show limited cross-protec-
tion (Yu et al, 2008). Significantly, broadly protective antibodies
recognizing conserved epitopes in the membrane proximal HA-stalk
or in the HA-head region have been discovered in mice and humans
recently (Wu & Wilson, 2017). The majority of broadly reactive HA
antibodies does not interfere with receptor attachment (Branden-
burg et al, 2013). They rather execute their protective effect via
interference with later steps in the viral replicative cycle or via Fc-
receptor (FcR)-mediated mechanisms, including antibody-dependent
cellular cytotoxicity (ADCC) (DiLillo et al, 2014). Vaccination with
inactivated influenza antigen alone is not able to efficiently induce
ADCC-activating antibodies in a non-human primate model (Jegas-
kanda et al, 2013). However, pre-existing ADCC-activating antibody
titers induced following natural infection could be boosted in
humans by inactivated vaccine, indicating that efficient priming is
imperative to elicit such antibodies (Jegaskanda et al, 2016).
Overall, the level of broadly reactive antibodies in infected or
vaccinated individuals is low due to immunodominance of variable
epitopes in the HA-head region (Ellebedy et al, 2014). However,
substantial antigenic changes of the HA-head region, for example as
consequence of antigenic shift, can lead to the expansion of HA-
stalk antibodies, in which the stalk-specific recall response outcom-
petes the de novo response against the shifted head (Li et al, 2012).
Immunization strategies employing chimeric HA (cHA) or headless
HA thus make use of this phenomenon (Steel et al, 2010; Hai et al,
2012; Li et al, 2012; Impagliazzo et al, 2015; Yassine et al, 2015).
However, since the production of these antigens either includes
vaccine bulk production in eggs or requires technically challenging
protein purification processes as well as adjuvants, alternative
vaccine platforms offer an attractive development perspective
(Ramezanpour et al, 2016; Grimm & Buning, 2017). Vaccinia- or
adenovirus-based vectors currently represent the most widely used
platforms in clinical vaccine trials (Ramezanpour et al, 2016).
However, adeno-associated virus (AAV) vectors might be particu-
larly suited as influenza vaccine carrier, since AAV is naturally repli-
cation-incompetent and apathogenic in humans, which was a
prerequisite for licensure as the first gene therapy vector for use in
humans (Grimm & Buning, 2017). The “gutless” AAV vectors can
be produced readily in cell culture according to good manufacturing
practice criteria, avoiding some of the aforementioned limitations
regarding vaccine production (Tripp & Tompkins, 2014). Also, AAV
vectors are re-administrable into the respiratory tract in the context
of pre-existing immunity without need to change the vector capsid
(Limberis & Wilson, 2006). Intriguingly, AAV vectors have been
used for passive immunization of mice and ferrets via expression of
broadly reactive HA-stalk antibodies in the respiratory tract (Balazs
et al, 2013; Limberis et al, 2013a,b; Adam et al, 2014; Laursen et al,
2018). Furthermore, active vaccination with AAV vectors expressing
internal (nucleoprotein (NP), matrix protein 1) and surface (HA)
influenza virus antigens protected mice from challenge infection
(Xin et al, 2001; Lin et al, 2009; Sipo et al, 2011). In the absence of
neutralizing antibodies against heterologous HA, the protection
against a non-matched influenza virus observed in that study was
attributed to the presence of cross-reactive T cells. However, the
quality and influence on protection of non-neutralizing antibodies
were neither evaluated nor compared to an inactivated vaccine
(Sipo et al, 2011). Furthermore, immunization with AAV-vectored
cHA or headless HA antigens has not been tested, and there are no
data as to the transferability of active AAV vector vaccination to the
ferret model, thought to most accurately represent human influenza
disease (Enkirch & von Messling, 2015). A detailed knowledge of
the effects of the AAV vector on the immune response is needed to
advance the AAV vector vaccine approach toward clinical develop-
ment (de Vries & Rimmelzwaan, 2016).
Here, we show that vaccination of mice with AAV-HA or AAV-
cHA induced broadly protective antibodies. Notably, protection was
associated with strong induction of FccR-activating antibodies.
Finally, we were able to show that three doses of an AAV-HA
vaccine conferred protection in ferrets against an (H1N1)pdm strain,
demonstrating the potential of the platform for further development.
Results
AAV9-vectors induce strong antigen expression in vitro
We evaluated the potency of AAV vectors expressing influenza virus
wild-type HA and NP, or cHA and headless HA antigens to confer
broad protection from influenza virus challenge in comparison with
an inactivated vaccine (Fig 1A). The AAV9 serotype used herein
was isolated from human tissue and efficiently transduces respira-
tory tissue of mice and ferrets (Gao et al, 2004; Limberis & Wilson,
2006; Limberis et al, 2013a). All vaccine constructs were based on
proteins encoded by the prototypic pandemic influenza virus
A/California/7/2009 (H1N1)pdm (Cal/7/9) (Fig 1B). The cHA
contained the stalk region of Cal/7/9 and head regions derived from
influenza A virus subtypes H2 (cHA1), H10 (cHA2), or H13 (cHA3)
that currently not circulate in humans. Furthermore, three different
headless HA constructs were tested, either containing merely the
deletion of the head region (headless HA, HL), or further modifi-
cations that increase their antigenicity (modified headless 1 and 2,
mHL1 and mHL2; Fig 1B; Impagliazzo et al, 2015; Steel et al, 2010;
Yassine et al, 2015). Initially, we assessed correct folding of the HA-
stalk within the constructs with the prototypic conformational stalk
antibody C179, as several broadly reactive antibodies recognize
conformational epitopes (Fig 1C; Okuno et al, 1993). Wild-type HA
and cHA3 displayed the C179 epitope, while cHA1 and mHL1
showed reduced binding to C179 (Fig 1C). cHA2, headless HA and
mHL2 were only faintly detectable with C179 (Fig 1C). Of note, all
cHA were detected by immune sera raised against the respective
parental influenza virus HA subtype, i.e., H2, H10, or H13, indicat-
ing correct recapitulation of the structure of the respective HA head
(Appendix Fig S1A and B). The order of the cHA for vaccination of
animals was set according to C179-staining intensity, i.e., cHA3–
cHA1–cHA2 (Appendix Table S1).
AAV2-vectors transencapsidated into AAV9 capsids were
produced, and integrity and identity of the AAV9 capsids were veri-
fied using the conformational capsid antibody ADK9 (Appendix Fig
S1C and D; Sonntag et al, 2011). All vector stocks contained high
amounts of encapsidated viral genomes (vg) and relatively
low amounts of empty capsids (Appendix Fig S1E and F).
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Correspondingly, robust in vitro AAV vector transduction rates were
achieved (Fig 1D and Appendix Fig S1G).
AAV-HA, AAV-cHA, AAV-NP, and inactivated vaccine induced
broadly reactive antibodies in mice
To assess immunogenicity of the AAV vector vaccines, 50 ll PBS
containing 1011 vg per mouse was applied equally to both nostrils
three times in 3-week intervals before being challenged with influ-
enza viruses. Control groups received either three times AAV-GFP
or two times Cal/7/9 whole-inactivated virus (WIV) via the same
route in order to be consistent with the application of the AAV-
vector vaccines (Fig 2A, Appendix Table S1). Earlier analysis had
shown that intranasally applied WIV vaccine elicits protective anti-
influenza immune responses in mice (Bhide et al, 2019). As
expected, all animals vaccinated with AAV vectors developed high
anti-AAV9 IgG titers which continued to increase over time
(Fig EV1A). Furthermore, AAV9-vector-neutralizing antibodies were
induced, which correlated with total anti-AAV9 serum IgG titers
(Fig EV1B and C).
The reactivity breadth of serum antibodies was tested against a
panel of ten influenza viruses from both antigenic group 1 (H1N1,
H2N3, H5N1, H13N6) and 2 (H3N2, H7N9, H10N7; Fig 2).
Immunization with AAV-HA, AAV-cHA, AAV-NP, and WIV induced
a significant increase of homologous Cal/7/9-specific serum IgG
antibody titers compared to pre-immune serum titers (Fig 2B).
Furthermore, AAV-HA- and AAV-NP-immunized mice had signifi-
cantly higher titers against Cal/7/9 compared to AAV-cHA or WIV
(Fig 2B). Interestingly, none of the AAV-vectored headless HA
vaccines induced detectable influenza-specific antibodies or anti-
bodies against the respective AAV-vectored antigen (Fig EV1D–F).
This might be due to the lack of immunodominant epitopes in these
antigens. Based on a report by Hessel et al (2014), we evaluated
whether the combination of AAV-mHL with the highly immuno-
genic AAV-NP would induce HA-stalk antibodies. This, however,
was not the case, and only NP reactive antibodies were induced
(Fig EV1G). Groups receiving AAV-vectored headless HA were
therefore not included in subsequent analyses.
AAV-HA, AAV-cHA, AAV-NP, and WIV induced broadened anti-
body responses (Fig 2D–G). AAV-HA triggered a strong response
mainly against H1N1 viruses, including pandemic H1N1 virus from
1918, but also H5N1 (Fig 2D). Although reacting weaker with Cal/
7/9 and the 1918 pandemic H1N1 viruses, AAV-cHA sera reacted
also with H5N1 and two of the cHA parental group 1 viruses (sub-
types H2 and H13) (Fig 2E). Both, AAV-HA and AAV-cHA, did,
however, not induce antibodies against group 2 viruses (Fig 2D and
A B
C D
Figure 1. (H1N1)pdm-based AAV-vectored antigens are strongly expressed in vitro.
A 3D structure of a HA trimer (PDB 3UBE generated with PyMol). Each monomer consists of a HA1 (dark gray) and HA2 (light gray) subunit. The trimer can be divided
into a membrane distal head which contains the RBS (yellow) and a proximal stalk region.
B HA and NP represent the Cal/7/9 wild-type proteins. Chimeric HA (cHA) 1 contains the head regions of H2 HA, cHA2 of H10 HA, and cHA3 of H13 HA, while they all
contain the Cal/7/9 HA-stalk region. Headless HA (HL) contains a deletion in the HA-head region (dashed line). Modified headless HA (mHL1 and mHL2) contain
stabilizing mutations (black boxes) and lack additional internal parts. All constructs were codon-optimized and carry a V5-tag at their C-terminus.
C Frequency of C179+ or V5-tag+ 293T cells 24 h after transfection of AAV vector plasmids as measured by flow cytometry. Symbols represent single experiments and
bars the mean  SE (n = 3).
D Immunoblot of 293T cells 72 h after transduction with AAV vectors at a MOI of 106. Antigen expression was detected with an anti-V5-tag antibody. Equal loading was
controlled with a GAPDH antibody (n = 3).
Source data are available online for this figure.
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E). In contrast, AAV-NP induced a strong antibody response cover-
ing viruses from both antigenic HA groups, including subtypes
H3N2 and H7N9, most likely due to the high conservation of NP
(Fig 2F). Unexpectedly, WIV vaccination also induced broadly reac-
tive antibodies covering several subtypes of group 1 and 2, though
at lower intensities (Fig 2G).
IgA antibodies confer protection to respiratory pathogens due to
their high local abundance in the airway mucosa (Asahi et al,
2002). We determined pre-challenge levels of serum IgA (Fig EV1H)
as well as post-challenge levels of IgA in lung homogenates (Figs 2C
and EV1I). AAV-HA and AAV-NP immunization induced IgA anti-
bodies in the serum as well as in the lung against Cal/7/9. In
contrast, IgA was not or barely detectable in serum and lung,
respectively, after AAV-cHA immunization. Only AAV-NP-immu-
nized mice mounted serum and lung IgA antibodies against heterol-
ogous A/Puerto Rico/8/1934 (H1N1) (PR8) virus (Fig EV1H and I).
Interestingly, increased levels of IgA were detectable in lung homo-
genates but not in sera of WIV-immunized mice against both Cal/7/
9 and PR8 (Figs 2C, and EV1H and I). In summary, antibodies were
induced at least against some group 1 HA including the subtypes
H1N1 and H5N1 after immunization with AAV-HA or AAV-cHA,
while AAV-NP and WIV immunization led to antibody responses
reacting with influenza A viruses from both antigenic groups.
Broadly reactive HA-specific antibodies are non-neutralizing
in vitro
To analyze the characteristics of the serum antibody responses, we
initially determined hemagglutination inhibition (HAI) and neutral-
izing antibody titers. The level of HAI+ antibodies that block the
RBS and interfere with attachment is a key parameter for evaluation
of currently licensed inactivated vaccines. Neutralizing antibodies,
though not necessarily binding directly to the RBS, can also inhibit
later steps in the viral replication cycle as well (Brandenburg et al,
2013). To capture such effects, we performed microneutralization
(MN) assays (He et al, 2015). HAI+ and MN+ antibodies against
the homologous Cal/7/9 virus were found only in animals immu-
nized with AAV-HA (Table 1). However, these antibodies were
A
D E F G
B C
Figure 2. AAV-vectored vaccines and WIV induce broadly reactive antibodies.
A Mice were intranasally given 1011 vg of AAV vector in 50 ll volume three times in 3-week intervals. 20 lg of Cal/7/9 WIV per 50 ll was given i.n. two times. Blood
samples were taken at indicated time points (red drops). After influenza challenge, mice were monitored for survival and weight loss for 2 weeks before necropsy.
B Total IgG ELISA titers expressed as area under the curve (AUC) against homologous Cal/7/9 virus of pre-immune and pre-challenge sera of individual animals of the
indicated vaccine groups (AAV-HA, -cHA, -GFP, WIV n = 18, AAV-NP n = 11). Background reactivity of pooled AAV-GFP pre-challenge serum is shown as dashed line.
ELISAs were performed in technical duplicates.
C IgA ELISA titers in post-challenge lung homogenates against Cal/7/9 of individual mice of the indicated vaccine groups (AAV-HA, -cHA, -GFP, -NP, WIV n = 11). of
the Cal/7/9 (blue symbols) and PR8 low-dose (red symbols) challenge groups. ELISAs were performed in technical duplicates.
D–G Total IgG ELISA titers expressed as log10 of the mean AUC against indicated viruses in pre-challenge sera in AAV-HA (D, n = 18)-, AAV-cHA (E, n = 18)-, AAV-NP (F,
n = 11)-, or WIV (G, n = 18)-immunized animals (gray area). Reactivity of sera of AAV-GFP-immunized animals is indicated as white area in the center of each web
diagram. ELISAs were performed in technical duplicates.
Data information: Statistical significance between pre-immune and pre-challenge serum was determined using Wilcoxon matched pairs test (###P < 0.001). Statistical
significance between vaccine groups was determined using Kruskal–Wallis test with Dunn’s multiple comparison testing (*P < 0.05, **P < 0.01, ***P < 0.001). Lines
indicate mean.
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specific for Cal/7/9 and did not react with another H1N1 or H3N2
virus. Sera from AAV-cHA-immunized animals were MN+ and
HAI+ against H13N6, i.e., the parental subtype of cHA3 used for
prime immunization, but were negative for all other tested viruses
including the parental subtypes of the cHA used for immunization 2
and 3 (H2, H10) (Appendix Table S1, Table 1). Intranasal WIV, as
well as AAV-NP and AAV-GFP did not induce HAI+ or MN+ anti-
bodies (Table 1). The lack of MN+ and HAI+ antibodies following
WIV application depended on the intranasal immunization route, as
intramuscular (i.m.) injection with the same vaccine preparation led
to the expected robust induction of MN+ and HAI+ antibodies
(Appendix Fig S2). These results indicate that immunization by
AAV in our scheme elicited MN+ and HAI+ antibodies toward the
HA-head domain of the virus used for prime immunization.
AAV-HA, AAV-cHA, and WIV induced distinct HA-specific
antibody profiles
Recent work on humoral responses against HA has raised great
interest into non-neutralizing antibodies that bind outside the
canonical antigenic sites, but are capable of activating ADCC or
other protective responses (Henry Dunand et al, 2016; Leon et al,
2016; Tan et al, 2016; Wu & Wilson, 2017). Hence, we investigated
in more detail the epitopes of HA-specific antibodies in the mouse
sera. We first analyzed via immunoblot the differential binding to
HA1 and HA2 subunits of four different H1N1 viruses spanning
more than 90 years of influenza virus evolution (Fig EV2A). HA1
contains the head region, whereas most of the stalk is located on
HA2. All serum pools were diluted equally allowing to compare the
relative abundances of antibodies recognizing either HA1 or HA2,
respectively, among the vaccine groups. AAV-HA vaccination
induced antibodies reacting with the HA1 domain of the pandemic
Cal/7/9 and A/Brevig Mission/1/1918 (BM/1/1918) viruses, but not
of PR8 or seasonal A/Brisbane/59/2007 (Bris/59/7) virus (Figs 3A
and EV2B). This is in line with the related antigenicity of the two
pandemic strains (Medina et al, 2010; Fig EV2A). AAV-HA serum
also detected the HA2 of the Cal/7/9, PR8, and Bris/59/7 strains,
indicating the additional induction of antibodies binding to the HA
stalk (Figs 3A and EV2B). The induction of stalk antibodies was also
suggested by reactivity of AAV-HA serum toward headless and
chimeric HAs that were in parallel confirmed to carry a native stalk
conformation as judged by C179 binding (Fig EV2C). Compared to
that, AAV-cHA immunization induced a stronger HA2 antibody
response recognizing all four H1N1 viruses, but no antibodies
against HA1 (Fig 3A). Interestingly, the difference in reactivity
between AAV-HA and AAV-cHA induced antibodies toward a
natively folded H1-stalk-antigen as measured by in-cell ELISA was
not as pronounced as toward the denatured antigen in immunoblot,
indicating that AAV-HA sera contain a considerable proportion of
conformational HA-stalk antibodies (Fig EV2C). An epitope screen
with overlapping 15-mer peptides derived from Cal/7/9 HA verified
the presence of HA-head and HA-stalk antibodies in the AAV-HA
sera as it identified five surface-exposed peptides including amino
acid positions 168–182 (Pep16), 308–322 (Pep30), 398–412 (Pep39),
418–432 (Pep41), and 488–502 (Pep48) reacting significantly
stronger with AAV-HA serum compared to AAV-GFP negative
control serum (Fig EV2D). Mapping of these peptides onto the 3D-
structure of H1N1 HA revealed that the identified epitopes included
amino acids surrounding the RBS, at the lateral site of the head and/
or the upper part of the stalk region, as well as at the membrane
proximal part of the HA stalk (Fig 3B). Interestingly, and quite unex-
pected, intranasal WIV consistently induced mostly HA2-specific
antibodies, too (Fig 3A). When given by the i.m route, however, the
WIV preparation elicited the expected spectrum of antibodies bind-
ing also to HA1 and containing HAI+ and MN+ activity confirming
its immunogenicity (Appendix Fig S2). No peptide with significant
binding was identified in the epitope screen with intranasal WIV or
AAV-cHA antisera, although a peptide with increased reactivity was
identified with AAV-cHA sera, which appeared to be buried within
the HA stalk (Fig EV2E (arrow) and F).
Upon acidification of the endosome HA undergoes major confor-
mational changes, which eventually results in fusion of viral and
endosomal membranes and release of the viral genome into the
cytoplasm. HA-stalk binding antibodies may interfere with these
steps and thus execute an inhibitory effect on viral replication
(Ekiert et al, 2011). However, antibodies preventing HA conforma-
tional changes were shown not to bind to the low-pH conformation
of HA (Friesen et al, 2014). Therefore, we analyzed by ELISA the
binding of serum antibodies to HA after pre-incubation at neutral to
acidic pH and after the removal of the HA1 subunit by treatment
with the reducing agent DTT at acidic pH. As expected, binding of
the conformational antibody C179 was strongly reduced at low pH
against Cal/7/9 and PR8 (Fig 3C). Sera induced by AAV-HA bound
to Cal/7/9 unless the HA1 subdomain was removed, indicating that
homologous binding was mediated mainly by antibodies against the
HA head (Fig 3D). This was, however, not the case for PR8, to
which binding was presumably mediated by HA-stalk antibodies
(Fig 3A and D). Interestingly, unlike C179, AAV-HA and AAV-cHA
induced sera-contained antibodies that bind to the low-pH confor-
mation of the HA stalk (Fig 3D and E). The even stronger binding
observed with AAV-cHA serum might result from exposition of









HAI 640 < 40 < 40 < 40 < 40 < 40
MN50 2,794 < 40 < 40 < 40 < 40 < 40
H1N1 (A/PR/8/34)
HAI < 40 < 40 < 40 < 40 < 40 < 40
MN50 < 40 < 40 < 40 < 40 < 40 < 40
H3N2 (A/X31)
HAI < 40 < 40 < 40 < 40 < 40 < 40
MN50 < 40 < 40 < 40 < 40 < 40 < 40
H13N6
HAI < 40 160 < 40 < 40 < 40 < 40
MN50 < 40 1,047 < 40 < 40 < 40 < 40
H2N3
HAI < 40 < 40 < 40 < 40 < 40 < 40
H10N7
HAI < 40 < 40 < 40 < 40 < 40 < 40
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epitopes after pH-induced conformational change, which are other-
wise buried within the HA stalk (Fig EV2E). Binding of WIV-
induced antibodies did not vary at different pH or with removal of
HA1 (Fig 3F), which was also the case for AAV-NP sera (Fig EV2G).
In conclusion, AAV-HA induced antibodies against both the HA
head and stalk, while AAV-cHA and WIV elicited mainly HA-stalk
reactive antibodies.
AAV-vectored vaccines induced broadly reactive
FccR-activating antibodies
To address whether AAV vector vaccination induced broadly reactive
antibodies with the ability to activate FccR and thereby upregulate
antiviral effector mechanisms, we used an assay that allows for sepa-
rate analyses of all four murine FccR (FccRI, FccRIIB, FccRIII, and
FccRIV) (Fig EV3A; Van den Hoecke et al, 2017). AAV-HA, AAV-NP,
and AAV-cHA vaccines clearly more potently induced Cal/7/9 virus-
specific FccR-activating antibodies thanWIV (Fig 4A). Moreover, only
the AAV-vectored vaccines but not WIV induced FccR-activating anti-
bodies against a heterologous virus strain, i.e., PR8, although at lower
levels (Fig 4B). Notably, AAV-HA, AAV-cHA, and WIV total PR8 anti-
body titers were not predictive for FccR antibody titers (Fig EV3B).
Interestingly, AAV-NP sera induced strong FccR-activating antibody
responses against both viruses (Fig 4A and B).
While it was initially proposed that only HA-stalk antibodies rely







Figure 3. AAV-HA, AAV-cHA, and WIV induce distinct HA-specific antibody profiles.
A Immunoblot analysis of purified H1N1 viruses A/California/7/2009 (Cal/7/9), A/Brevig Mission/1/1918 (BM/1/1918), A/Puerto Rico/8/1934 (PR8), or A/Brisbane/59/2007
(Bris/59/7) separated under reducing and denaturing conditions. Uncleaved HA0 and cleavage products HA1 and HA2 were detected with pooled pre-challenge sera
(AAV-HA, -cHA, -GFP, WIV n = 18, AAV-NP n = 11) as indicated (n = 3).
B Significant peptides identified in the epitope screen with AAV-HA pooled pre-challenge serum ((AAV-HA, -cHA, -GFP, WIV n = 18, AAV-NP n = 11; data shown in
Fig EV2) were mapped onto HA1 (red) and HA2 (blue) of the trimeric HA (PDB 3UBE generated with PyMol) (n = 3, technical duplicates). The position of the RBS
(yellow) and the C179 epitope (dashed line) is marked.
C–F Binding of C179 (C), or antibodies present in AAV-HA (D), AAV-cHA (E), or WIV (F) pooled pre-challenge sera (n = 18 mice per group) to Cal/7/9 or PR8 virus after
incubation of the virions at pH = 7.2, 5.8, 5.4, 5.0, 4.4 or 4.4 + DTT to induce conformational changes in HA or remove the HA1 subdomain. Mean  SD (n = 3, in
technical triplicates). Statistical significance between pH = 7.2 and other conditions was determined using Kruskal–Wallis test with Dunn’s multiple comparison
testing (*P < 0.05, **P < 0.01).
Source data are available online for this figure.
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recently been revised to acknowledge that all broadly reactive HA
antibodies require activation of FccR to mediate protection (DiLillo
et al, 2016). Thus, we investigated whether both head and stalk
antibodies contained in the AAV-HA sera could activate FccR. To
quantify the influence of the HA-head domain on FccR activation,
we assessed serum antibodies with transfected target cells express-
ing either complete HA or a stalk-only HA (Fig EV3C and D). In fact,
the signal observed with the complete HA was much more
pronounced in comparison with HA-stalk-only expressing cells, indi-
cating that AAV-HA induces FccR-activating stalk and head antibod-
ies (Fig 4C). As expected, as AAV-cHA-induced sera contained
mainly HA-stalk antibodies (Fig 3A), signal intensities were compa-
rable with both antigens, whereas WIV antiserum stimulated very
poorly (Fig 4C). These results indicate that AAV-HA, AAV-NP, and
AAV-cHA vaccines potently induce broadly reactive FccR-activating
antibodies. Furthermore, AAV-HA, in contrast to AAV-cHA, induced
FccR-activating antibodies against the HA-stalk and HA-head
regions.
AAV-HA, AAV-cHA, and AAV-NP protect mice from homologous
and heterologous challenge
To assess homologous and heterologous protection, groups of mice
were challenged with lethal doses of the divergent H1N1 viruses
Cal/7/9 or PR8 that differ in their HA1 amino acid sequence by
more than 25% (Fig EV2A). After Cal/7/9 challenge, AAV-HA- and
AAV-NP-immunized animals were completely protected, while all
animals of the negative control group (AAV-GFP) succumbed to the
infection (Fig 5A). AAV-cHA and WIV protected four out of five
animals. Only AAV-HA-immunized mice did not show any sign of
weight loss, likely corresponding to the presence of neutralizing
antibodies (Figs 5B and EV4A, and Table 1). All other groups
showed about 10% mean maximum weight loss. Nevertheless,
surviving animals recovered quickly and were able to clear the virus
at the end of the 14-day monitoring period (Figs 5B and EV4B).
To evaluate protection against a heterologous H1N1 strain, mice
were challenged with PR8. Although lethal for control animals
(AAV-GFP), the dose used for the first challenge experiment did not
reveal differences in survival rates of vaccinated groups (Fig 5C).
However, AAV-HA-, AAV-cHA-, and AAV-NP-immunized animals
showed only moderate mean maximum weight loss (3–4.5%),
which was significantly less than in the AAV-GFP-vaccinated
animals (21%) (Figs 5D and EV4C). In contrast, WIV-immunized
animals experienced up to 10% mean maximum weight loss. As
with Cal/7/9 challenge, those animals were finally able to clear the
virus, despite the absence of pre-existing neutralizing antibodies
against PR8 (Fig EV4D, Table 1). This result indicated that the
AAV-vectored vaccines were superior to the inactivated vaccine
against heterologous challenge in reducing the extent of weight loss.
To evaluate the effect of the HA-based AAV vector vaccines on
protection, we conducted another PR8 challenge with a higher inoc-
ulation dose. Here, the majority of mice immunized with AAV-HA
or AAV-cHA were protected from severe disease and death (71%;
5/7), which was also reflected by mean maximum weight loss of
10% (Figs 5E and F, and EV4E). In contrast, WIV-immunized and
negative control (AAV-GFP) animals were not protected (Fig 5E and
F). Interestingly, at 3 days post-infection with PR8, virus titers in
the lungs were comparable among all groups. At the end of the
monitoring period, however, only AAV-HA and AAV-cHA vaccina-
tion led to a significant reduction in mean lung virus titers compared
to the other groups (Fig EV4F). In summary, these results indicate
that three doses of AAV-HA or AAV-cHA were superior to two doses
of WIV in reducing mortality and disease severity against heterolo-
gous influenza challenge in mice.
AAV-vectored vaccines reduce disease severity in ferrets
The protective efficacy of AAV-vectored vaccines was finally
assessed in ferrets, as they most closely reproduce the course of
human influenza (Enkirch & von Messling, 2015). While focusing
on HA-based vaccines, groups of four animals were vaccinated three
times in 4-week intervals with AAV-HA, AAV-cHA, or AAV-GFP
(Fig 6A). As control, one group was given two doses of the commer-
cial quadrivalent influenza vaccine (QIV) of season 2017/18 by the
intramuscular route. The H1N1 component of QIV of this season
contained A/Michigan/45/2015 (H1N1)pdm which is closely related
to Cal/7/9. In fact, ferret convalescent sera raised against Cal/7/9
react undistinguishably with A/Michigan/45/2015 (WHO, 2018c).
All animals except for the AAV-GFP group developed influenza
virus-specific antibodies (Fig 6B). However, a statistically significant
continuous increase of antibody titers over time was only seen in
the AAV-HA group. As observed in mice, HAI+ and MN+ antibodies
against the homologous Cal/7/9 viruses were only found in AAV-
HA-immunized animals (Fig 6B). To exclude that QIV immunization
induced HAI+ and MN+ antibodies specific for A/Michigan/45/
2015 virus but not Cal/7/09, we repeated these assays with the
respective virus. As with Cal/7/9, only AAV-HA-immunized ferrets
mounted MN+ or HAI+ antibodies against A/Michigan/45/2015
(Fig EV5A and B).
Ferrets were sublethally challenged with 105 TCID50/animal of
the early (H1N1)pdm isolate A/Mexico/InDRE4487/2009, which
can cause severe disease in ferrets (Meunier et al, 2012). During the
3-day challenge period, clinical signs of influenza were monitored,
and weight and temperature were measured. At day 3 post-infec-
tion, animals were sacrificed, and nasal turbinates, trachea, and
lungs were collected and processed for virus titration and/or
histopathological examination (Fig 6A). All animals developed clas-
sical signs of influenza disease starting on day 1, including serous
nasal exudate, congestion, frequent sneezing, wheezing, and
depression (Fig 6C). However, ferrets receiving AAV-HA or AAV-
cHA recovered more quickly as evidenced by a return to normal
activity levels and improvement of respiratory signs compared to
QIV and AAV-GFP-immunized groups. Moreover, for AAV-HA-
immunized animals, a milder clinical course was associated with
high MN+ and HAI+ antibody titers (Fig EV5D). Upon infection,
body temperature increased in all animals, which continued to
increase in QIV-immunized animals until day 3 post-infection, while
only a short fever peak was seen in the AAV vector vaccinated
groups (Fig 6D). Moreover, maximum weight loss of QIV-immu-
nized animals was more severe (up to 10%) compared to the other
groups (3–6%; Fig 6E).
Virus was isolated from the respiratory tract of all animals to
various extents, indicating that no sterile immunity was induced
(Fig 6F). Significantly, AAV-HA-immunized ferrets had reduced
virus titers in tissue homogenates of nasal turbinates, trachea, and
lung, while all other groups showed higher virus titers (Fig 6F).
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Furthermore, neutralizing antibody titers in AAV-HA-immunized
animals correlated with reduced viral titers in the nasal turbinates
(Fig EV5E). Immunohistochemical staining detected influenza virus
antigen in the lungs of all animals yet with clear differences between
groups. The strongest differences were observed between the AAV-
HA-immunized ferrets, with only rare virus antigen in the submu-
cosal glands and bronchial epithelial cells when compared to the
AAV-cHA- or AAV-GFP-immunized ferrets, which had massive
amounts of antigen-expressing cells in both locations (Figs 6G and
H, and EV5F and G). The load of virus antigen in QIV-vaccinated
ferrets was in between the AAV-HA-vaccinated animals and the two
other groups (Fig 6G and H). Also, all ferrets developed signs of an
influenza virus-induced bronchio-interstitial pneumonia, although
at varying degrees. Damage of bronchi and bronchioles was most
pronounced in AAV-GFP-immunized animals (Fig EV5H), while
lesions of lung interstitium as well as submucosal glands were more
severe in AAV-cHA- and QIV-immunized animals (Figs 6I and J,
and EV5I). Ferrets receiving AAV-HA had less severe lesions in the
conducting airways and lung compared to animals from the other
groups (Fig EV5H–J). These results indicate that AAV-HA and AAV-
cHA immunization reduced the disease severity after homologous
influenza virus infection in ferrets. However, only with AAV-HA
this was also associated with reduced virus replication and
pathogenesis.
Discussion
Conventional inactivated vaccines fail to elicit broadly protective
antibodies recognizing the HA stalk, as the dominant immune
response in mice (Altman et al, 2015) and humans (Ellebedy et al,
2014) is directed against variable antigenic sites in the HA head.
Development of strategies which shift the focus of the immune
response toward conserved HA epitopes has thus become an impor-
tant research objective (Krammer, 2017). Toward this goal, sequen-
tial immunizations with different chimeric HA or headless HA were
shown to trigger broadly reactive stalk antibodies (Impagliazzo




Figure 4. AAV-vectored vaccines but not WIV induce broadly reactive FccR-activating antibodies.
A, B Influenza virus-specific activation of the murine FccRI, FccRII, FccRIII, and FccRIV by antibodies in pooled pre-challenge sera (AAV-HA, -cHA, -GFP, WIV n = 18, AAV-
NP n = 11 mice per group). MDCKII cells were infected with Cal/7/9 (A) or PR8 (B) before mouse serum and FccR-expressing reporter cells were added. Influenza-
specific Fc-FccR interaction induces the production of IL-2 in the FccR-expressing reporter cell, which was measured by anti-IL2 ELISA (n = 3, technical duplicates).
Mean  SE.
C HA-specific activation of FccR by AAV-HA, AAV-cHA, or WIV pooled pre-challenge sera (n = 18 mice per group). MDCKII cells were transfected with wild-type HA
(pAAV-HA) or a stalk-only HA (pAAV-mHL1) before mouse serum and FccR-I-expressing reporter cells were added (n = 2, technical duplicates). Mean  SE.
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et al, 2017). Other challenges associated with the vaccine manufac-
turing cycle including egg-based production might, however, not be
overcome by these candidate antigens (Impagliazzo et al, 2015;
Yassine et al, 2015, Register ECT, 2017). Thus, it has been appreci-
ated that innovative delivery platforms such as viral vectors could
be an important element on the quest for a universal and long-
lasting influenza vaccine (Erbelding et al, 2018; Ortiz et al, 2018).
Commonly used viral vectors have proven their efficacy as influenza
vaccine carriers in multiple studies (de Vries & Rimmelzwaan,
2016). However, most “traditional” vectors express viral gene prod-
ucts and/or induce strong inflammatory responses, causing safety
concerns. Reports regarding genotoxicity have been limited to wild-
type AAV infection (Nault et al, 2015), while AAV vectors show an
advantageous safety profile (Buning & Schmidt, 2015). AAV vectors
represent the first EMA- and FDA-approved (FDA, 2018) vector
system for use in human gene therapy and were successfully used
in preclinical active immunization studies against several infectious
diseases (Nieto & Salvetti, 2014). Furthermore, AAV vectors can be
produced in cell culture, stored at room temperature, and applied
without needles into the nose, offering possible solutions to chal-
lenges regarding production and application of the current vaccine
(Grimm & Buning, 2017).
Using the AAV vector, our study confirmed that sequential
immunization with different cHA focuses the humoral response to
the HA stalk and provides heterologous protection. However, it was
unexpected to find that also AAV-vectored full-length HA was able
to elicit not only neutralizing, but also substantial levels of HA-
stalk-specific antibodies. This conclusion is supported by the obser-
vations that AAV-HA-induced antibodies (i) detected the HA2
domain in the immunoblot assay (Fig 3A), (ii) bound to peptides
derived from the HA-stalk region (Fig 3B), and (iii) reacted with a
natively folded HA-stalk construct, as measured by in-cell ELISA
(Fig EV2C). Hence, AAV-HA immunization induced conformational
and non-conformational HA-stalk antibodies. Additionally, AAV-HA
immunization had in contrast to AAV-cHA the benefit of mounting
HAI+ and MN+ antibodies toward the HA head of the homologous
H1N1 virus. The importance of broadly reactive antibodies against
the HA head employing novel modes of action has been demon-
strated recently (Bangaru et al, 2019; Watanabe et al, 2019). Such
antibodies might be induced by AAV-HA as well. AAV-HA and
AAV-cHA also induced FccR-activating antibodies targeting homolo-
gous and heterologous viruses (Fig 4), which is a desirable property
as most broadly reactive antibodies require activation of FcR to
mediate protection (DiLillo et al, 2014, 2016). Interestingly, AAV-
HA immunization triggered FccR-activating antibodies not only
toward the HA stalk, but also against epitopes present only in the
context of full-length HA, likely located in the HA-head domain
(Fig 4). Consequently, we observed that immunization with AAV-
HA conferred sterile immunity against a homologous virus, and
heterologous protection toward a drifted H1N1 virus. The precise
extent of FccR-mediated effector functions in the observed heterolo-
gous protection by AAV-HA and AAV-cHA remains to be deter-
mined. While Cal/7/9-specific FccR-activating responses were more
potent with the activating FccR (I, III, and IV), which are associated
with induction of ADCC, highest titers of heterologous FccR-acti-
vating antibodies were reached with the inhibitory FccR-IIB. Thus, a
regulatory role of these antibodies might be indicated, favoring for
example enhanced B-cell responses (Wang et al, 2015).
The induction of broadly binding but non-neutralizing serum
antibodies by intranasal WIV vaccination in our study recapitulates
and extends observations by others (Bhide et al, 2019). It was actu-
ally suggested that protection mediated by intranasally applied WIV
involves cellular and mucosal immunity (Dong et al, 2018; Bhide
et al, 2019) including elevated levels of IgA that might have
conferred protection against homologous and mild heterologous
challenges in our study. However, WIV-induced responses did not
protect against a harsh heterologous challenge, which correlated
with the failure to induce heterologous FccR-activating antibodies.
Previous studies described a restriction of the immune response
to HA within the same antigenic group of influenza A viruses
(Krammer et al, 2013; Margine et al, 2013), which was also appar-
ent with the AAV-HA or AAV-cHA immunization regimens tested




Figure 5. AAV-HA, AAV-NP, and AAV-cHA induce broad protection against
H1N1 challenge.
A–F Mice were vaccinated three times with AAV vectors or two times with
WIV and then challenged with a lethal dose of homologous influenza
virus (Cal/7/9) (A, B; n = 5) or two different lethal doses of the
heterologous PR8 strain (C, D; n = 6 and E, F; n = 7). Survival was
monitored over a 14-day period and is depicted as Kaplan–Meier plot (A,
C, E). Weight loss was determined during the 14-day period, which is
shown in relation to the weight at day 0 (B, D, F). Mean  SE. Statistical
significance between negative control group (AAV-GFP) or WIV group (E),
and each vaccine group was determined using log-rank (Mantel–Cox)
test (*P < 0.05, **P < 0.01).
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AAV-vectored combinations of HA components, e.g., H1 and H3, or
inter-group stalk consensus constructs for the capacity to expand
protection to both antigenic groups. Our findings suggest that AAV
vectors might also be explored as useful carriers for other conserved
viral antigens such as NA or M2e (Krammer et al, 2018).
Unexpectedly, none of three tested headless HA appeared to be
immunogenic or conferred protection when expressed from an AAV
vector (Fig EV5G–J). Other headless HA-based approaches relied on
heterologous prime/boost regimens (DNA/VLP, i.n./i.m.), carrier
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immune responses (Steel et al, 2010; Impagliazzo et al, 2015;
Yassine et al, 2015). A recent study suggested that poor immuno-
genicity of headless HA was associated with the inability to robustly
induce T-follicular helper cells, thus limiting B-cell responses, which
could only be overcome by linkage to an immunogenic carrier (Tan
et al, 2018). Interestingly, lack of immunogenicity was also found
with a MVA vector expressing headless HA (Hessel et al, 2011).
This could be circumvented by vectored co-expression of the
strongly immunogenic NP, probably allowing for more efficient
induction of HA-stalk antibody-secreting cells after intermolecular
help by NP-specific CD4 T cells (Hessel et al, 2011; Alam et al,
2014). In our study, a bivalent AAV-mHL1 + AAV-NP vaccine had
no such effect, probably because mHL1 and NP had to be expressed
from two AAV vectors due to the restricted packaging capacity,
thereby limiting simultaneous uptake of both antigens into one cell.
Thus, an AAV-vectored approach solely based on headless HA does
currently not seem to be feasible.
AAV-NP immunization induced a remarkably broad antibody
response covering all tested influenza viruses and capable to acti-
vate FccR, despite the fact that NP is considered a major stimulus of
cytotoxic T-cell immunity (Sipo et al, 2011). Previous studies
suggested a protective capacity of NP-specific FccR-activating anti-
bodies (Vanderven et al, 2016). However, the exact mechanism
remains unclear, since these antibodies target a viral antigen
supposedly localized in the interior of the virion or host cell
(Bodewes et al, 2013). Besides ADCC induction, FccR regulates
innate and adaptive immunity, including antibody responses them-
selves by regulation of B-cell selection, maturation, and survival
(Bournazos & Ravetch, 2017). The finding that AAV-NP induced
antibodies potently activated the murine inhibitory FccRIIB might
suggest rather a regulatory role of these antibodies. However, both
humoral and cellular immunity will likely contribute to NP-
mediated protection. Further experiments are needed to extend
knowledge on involved protective mechanisms (Carragher et al,
2008; Mullarkey et al, 2016; He et al, 2017).
In ferrets that are considered the animal model recapitulating
most aspects of human influenza, we could for the first time show
that active immunization with AAV-HA or AAV-cHA confers protec-
tion against a homologous viral challenge. However, only AAV-HA-
immunized ferrets showed reduced virus replication and lung
pathology, likely due to induction of neutralizing antibodies against
(H1N1)pdm viruses in these animals. Though AAV-cHA immuniza-
tion symptomatically protected ferrets as indicated by a reduced
clinical score, no reduction in virus titer was seen. This is in
contrast to a study where vaccination with different cHA expressed
by influenza B-, VSV-, or AdV vectors reduced viral titers (Krammer
et al, 2014). Unexpectedly, AAV-GFP-immunized ferrets, though
showing an increased clinical score, lost least weight during chal-
lenge. It can only be speculated on the reasons, but this might be a
consequence of the lack of protective antibody allowing for more
efficient replication and severe damage of the upper respiratory tract
compared to the other groups, which might have resulted in a dif-
ferent manifestation of disease. This topic clearly requires further
investigations.
The observed lack of protection in QIV-immunized ferrets is
counterintuitive. However, this finding recapitulated observations
by others and likely depended on a failure to induce HAI+ antibod-
ies by the commercial, non-adjuvanted human vaccine (Baras et al,
2011; Nachbagauer et al, 2017; Liu et al, 2019). Neither in ferrets
nor mice, change of the AAV vector capsid was required to achieve
high influenza-specific antibody titers upon intranasal vaccination,
even in the presence of AAV9-neutralizing serum antibodies. This
finding is in line with observations by others (Limberis & Wilson,
2006). Seroprevalence of AAV9-neutralizing antibodies in humans is
generally low (Boutin et al, 2010), suggesting an advantage over
other viral vectors in the context of pre-existing immunity which
critically influences transduction efficiency (Nachbagauer et al,
2015; Ryder et al, 2015). Current production capacities for AAV
vectors allow the production of batches suitable for midscale clinical
studies, but recent advances give a perspective that future large-
scale AAV vector production and purification platforms will be able
to match the demand for higher number of AAV vector-based
vaccine doses (Nass et al, 2017).
Here, we show that vaccine delivery by the AAV-HA and cHA
vectors resulted in the favorable induction of broadly reactive and
FccR-activating antibodies, which was not achieved with inactivated
vaccine given either by the intranasal (this study) or intramuscular
routes (Angeletti et al, 2019). Important factors leading to this
finding included most likely continuous generation of antigen by
respiratory cells after mucosal immunization, and the lung-specific
environment, which influences processing and presentation of anti-
gen to cells of the adaptive immune system (Angeletti et al, 2017).
We speculate that this vectored delivery resulted in more effective
priming of rare B cells recognizing conserved epitopes in the HA
stalk (Ellebedy et al, 2014). Hence, AAV vectors might be usable in
a naı̈ve human population to efficiently prime a broadly reactive B-
cell memory, or to boost and maintain such a response in influenza
experienced individuals (Andrews et al, 2015). In conclusion, the
◀ Figure 6. AAV-HA and AAV-cHA have a protective effect in ferrets.A Ferrets (n = 4 per group) were immunized with AAV vectors or quadrivalent inactivated vaccine (QIV). Serum was obtained at indicated time points (red drops).
After challenge with a Cal/7/9-like (H1N1)pdm strain clinical signs, temperature and weight loss were monitored. At 3 dpi, animals were sacrificed and necropsied.
B Cal/7/9-specific serum antibody titers in individual sera at indicated time points. Black lines: individual animals, red lines: mean titer. Statistical significance
between pre-immune and immune sera was determined using Friedman test with Dunn’s multiple comparison testing (*P < 0.05, **P < 0.01). The lower table
indicates Cal/7/9-specific MN50 and HAI mean titers. Assays were performed in technical duplicates.
C–E Clinical score (C), body temperature (D), and relative weight (E) during challenge period. Statistical significance between pre-immune and immune sera was
determined using Friedman test with Dunn’s multiple comparison testing (AAV-HA ##P < 0.01; AAV-cHA §§P < 0.01; AAV-GFP $P < 0.05; $$P < 0.01; QIV *P < 0.05).
Mean  SD.
F Virus titers in nasal turbinates (NT), trachea, or lung homogenates. Statistical significance between AAV-GFP and vaccine groups was determined using Kruskal–
Wallis test with Dunn’s multiple comparison testing (*P < 0.05). Lines indicate the GMT. Assays were performed in technical duplicates.
G, H IHC staining of submucosal glands (SMG) (G) or bronchi (H) with an anti-H1N1 polyclonal antibody (bar: 100 lm; red: influenza antigen (Neufuchsin); blue: nuclei
(hematoxylin)).
I, J H&E-stained histological sections of bronchi (I) and lung parenchyma with alveolar epithelial cells (AEC, J). Arrowheads: areas of suppurative bronchitis/
bronchiolitis; arrows: interstitial pneumonia, necrosis of AEC (bar: (I) 100 lm; (J) 50 lm).
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data suggest a large potential for the development of AAV vectors
into a carrier for a broadly protective influenza vaccine.
Materials and Methods
AAV vector design and production
All antigens were based on HA or NP of Cal/7/9 (H1N1)pdm virus
and were codon-optimized to mammalian gene expression and de
novo synthesized (GeneArt, Thermo Fisher Scientific, Regensburg,
Germany). The construction of AAV-HA and AV-NP has been
described before (Sipo et al, 2011). The initial headless HA (HL)
gene was constructed by replacement of the sequence between
codons of cysteine52 and cysteine277 (“head”) of HA1 with a tetra-
glycine linker as described before (Steel et al, 2010). Three different
chimeric HAs (cHA) were constructed by insertion of the head
regions, i.e., regions cysteine52–cysteine277, derived from of avian
influenza A viruses of the subtypes H2, H10, or H13 into the respec-
tive region of the headless HA, thereby removing the glycine linker.
Modified headless proteins 1 and 2 (mHL1 and mHL2) were
constructed by transferring the mutations described (Impagliazzo
et al, 2015; Yassine et al, 2015) into the Cal/7/9 HA. All constructs
were inserted into the AAV vector plasmid in between the AAV2
ITRs, downstream of a CMV promoter and an irrelevant intron and
upstream of a V5-tag and polyadenylation/termination signal.
AAV9-vector stocks were prepared by triple transfection of the AAV-
vector plasmid (pAAV), p5E18-VD2/9 (AAV2 Rep, AAV9 Cap), and
pHelper (adenovirus helper genes; Addgene) into 293T cells for
72 h. Cells were lysed with sodium deoxycholate, and non-encapsi-
dated DNA was digested with benzonase (Merck, Darmstadt,
Germany). AAV vector particles were purified via isopycnic centrifu-
gation through an iodixanol (Axis-Shield, Dundee, UK) step gradient
and concentrated with Amicon Ultra-15 filter units (Merck). High
quantity and quality of AAV9-vector stocks were verified by
infectious titer determination, electron microscopy, ELISA, and
TaqMan qPCR (forward primer: 50-TGGAGTTCCGCGTTACAT
AACTTAC-30; reverse primer: 50-CTATTGGCGTTACTATGGGAAC
ATAC-30, probe: 50-FAM-CCTGGCTGACCGCCCAACGAC-BBQ-30)
using Platinum-Taq DNA Polymerase (Thermo Fischer Scientific,
Hennigsdorf, Germany) with an initial denaturation step at 95°C—
10 min followed by 40 cycles of 95°C—15 s; 60°C—20 s; 72°C—
10 s in a Roche LightCycler 480. Tenfold dilutions of SmaI-digested
pAAV plasmid DNA (1 ng/ll) were used as standard to calculate
absolute amounts of AAV vector genomes per microliter.
Cell lines and influenza viruses
293T were maintained in DMEM, and MDCKII cells in MEM supple-
mented with 10% FBS, L-glutamine, and penicillin/streptomycin.
Cells were taken from the tissue culture collection of RKI’s unit 17
and tested negative for mycoplasma contamination. Infections with
influenza viruses were performed in cell culture medium with 0.2%
BSA and TPCK-treated trypsin. Influenza A viruses (BSL2: A/Cali-
fornia/7/2009 ((H1N1)pdm); A/Puerto Rico/8/1934 (H1N1); A/
Widgeon/DK/66174/2004 (H2N3); X31 (H3N2); A/Panama/2007/
1999 (H3N2); A/Mallard/NVP/9417/2004 (H10N7); A/Gull/MD/
704/1977 (H13N6); BSL3: HA/NA-1918 × WSN/1933 reassortant
(H1N1); A/Viet Nam/1203/2004 (H5N1); A/Anhui/1/2013 (H7N9))
were propagated in 11-day-old embryonated chicken eggs. Allantoic
fluid harvested from infected eggs was purified by ultracentrifuga-
tion through a 20% sucrose cushion and resuspended in PBS before
protein content was determined via BCA (Thermo Fischer Scientific,
Hennigsdorf, Germany). Infectious titers were determined by plaque
assay on MDCKII cells. Whole-inactivated Cal/7/9 reassortant virus
(X-181) (WIV) used for vaccination of mice was kindly provided by
Othmar Engelhardt (National Institute for Biological Standards and
Control (NIBSC), Potters Bar, UK). Briefly, virus was grown on 11-
day-old embryonated chicken eggs, inactivated with b-propiolac-
tone, and purified by ultracentrifugation through a 20% sucrose
cushion. Protein content was determined by Lowry assay. A sample
was deglycosylated and separated on reducing SDS–PAGE, and viral
protein content was determined with Coomassie staining. Antigenic-
ity of the preparation was verified using single-radial diffusion
assay with Cal/7/9-specific sheep serum.
Indirect immunofluorescence microscopy and flow cytometry
293T cells were transfected with AAV vector plasmids for 24 h
using Lipofectamine 2000 (Thermo Fisher Scientific) according to
the manufacturer’s instruction. Cells were fixed, permeabilized,
blocked, and immunostained with anti-V5-tag (1:250; SV5-Pk1;
Bio-Rad, München, Germany), C179 (1:250; M145; TaKaRa,
Kusatsu, Japan) antibody, rabbit hyperimmune serum against the
influenza subtypes H2, H10, and H13 (1:500; 11688-RP01-100,
11693-RP01-100, 11721-RP01-100 Sino Biological Inc., Eching,
Germany), or animal serum followed by suitable secondary anti-
body coupled to AlexaFluor488 (1:1,000; Thermo Fisher Scien-
tific). Nuclei were stained with DAPI. Cells were analyzed using a
LSM 780 confocal laser scanning microscope (Zeiss, Jena,
Germany). For quantification of V5-tag or C179 or H2-, H10- and
H13 HA-positive cells, samples prepared the same way were
analyzed in a FACSCalibur cytometer (BD Biosciences, Heidelberg,
Germany).
Immunoblotting
293T cells were transfected with AAV vector plasmids for 48 h
using Lipofectamine 2000 (Thermo Fisher Scientific) according to
the manufacturer’s instruction. Alternatively, 293T cells were
transduced with AAV vector preparations at an MOI of 106 by
adding the amount of virus diluted in PBS directly to the cell
culture medium for 72 h. Cell lysates were prepared in RIPA buffer
(10 mM Tris/HCl (pH = 8), 150 mM NaCl, 0.5 mM EDTA
(pH = 8), 0.1% SDS, 1% Triton X-100, protease inhibitor) with
beta-mercaptoethanol and boiled, before samples were separated
by reducing SDS–PAGE under denaturing conditions and trans-
ferred onto nitrocellulose membrane. Western blotting was
performed by incubation with anti-V5-tag (1:1,000; SV5-Pk1) anti-
body and suited secondary antibody coupled to horseradish peroxi-
dase (HRP) (1:10,000; Agilent Technologies, Santa Clara, USA).
Equal loading of samples was controlled with GAPDH antibody
(1:1,000) staining.
4–8 lg per lane of sucrose-purified influenza viruses was sepa-
rated on SDS–PAGE under denaturing conditions and transferred
onto nitrocellulose membrane. Amount loaded per lane was
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normalized to yield equal intensities of HA2 with an anti-HA2 anti-
body (1:500; orb10765; Biorbyt, Eching, Germany). Western blotting
was performed by incubation with mouse serum (1:500) and suited
secondary antibody coupled to HRP (1:10,000; Agilent Technolo-
gies). Blots were developed on X-ray films (Thermo Fischer Scien-
tific) after addition of SuperSignalTM West Dura Extended Duration
Substrate (Thermo Fischer Scientific).
Mouse serum and lung homogenate ELISA
For serum ELISA, MaxiSorbTM ELISA plates (Thermo Fischer Scien-
tific) were coated with 4–8 lg/ml purified influenza virus or
approximately 1 × 1010 vg/ml AAV9 empty capsids in 50 ll 50 mM
carbonate/bicarbonate buffer (pH = 9.6) overnight at 4°C. Plates
were blocked with 3% skim milk in PBST0.05% before twofold serum
dilutions in 50 ll blocking buffer were added and plates were incu-
bated 90 min at 37°C. For lung homogenate ELISA, plates were
coated as mentioned above. Plates were blocked with 1% BSA in
PBST0.05%, before 50 ll of a twofold dilution of lung homogenates
in PBST0.05% was added for 1 h at 37°C. After washing, plates were
incubated with anti-mouse-IgG-HRP (1:1,000; Agilent Technologies)
or anti-mouse-IgA-HRP (1:1,000; Thermo Fischer Scientific) anti-
body for 45 min at 37°C before plates were washed again and 1-
StepTM Ultra TMB-ELISA Substrate Solution (Thermo Fischer Scien-
tific) was added for 1–10 min until color reaction was stopped with
1 M H2SO4. Optical density was measured at 450 nm (OD450 nm),
and the area under the curve was determined using GraphPad Prism
software.
HA conformational change ELISA
MaxiSorbTM ELISA plates (Thermo Fischer Scientific) were coated
with 4–8 lg/ml purified influenza virus in 50 ll carbonate/bicar-
bonate buffer (pH = 9.6) overnight at 4°C. 100 ll per well of acetate
buffer at different pH (7.2, 5.8, 5.4, 5.0, 4.4, and 4.4 + 0.1 M DTT)
was added at RT for 30 min. Plates were washed two times, and
ELISA was performed as described above.
In-cell ELISA
MDCKII cells were transfected with pAAV-HA, pAAV-mHL1 +
transmembrane region or with pcHA3 for 48 h using Lipofectamine
2000 (Thermo Fisher Scientific). Cells were fixed, permeabilized,
blocked, and incubated with AAV-HA, AAV-cHA, or AAV-GFP
mouse serum (1:250), or C179 (1:250) for 1 h at 37°C. After wash-
ing, cells were incubated with anti-mouse-IgG-HRP (1:1,000; Agilent
Technologies) for 1 h at 37°C before plates were washed again, and
1-StepTM Ultra TMB-ELISA Substrate Solution (Thermo Fischer Scien-
tific) was added for 10 min until color reaction was stopped with
1 M H2SO4. Optical density was measured at 450 nm (OD450 nm),
and values were normalized to AAV-GFP-negative control values.
Immunoperoxidase monolayer assay
Immunoperoxidase monolayer assay (IPMA) was used to determine
total antibody titers in ferret sera against Cal/7/9 virus and was
done as described previously (Walz et al, 2018). Briefly, MDCKII
cells were infected with Cal/7/9 at a multiplicity of infection of 0.01
and incubated at 37°C for 2 days. Cells were then washed with 30%
PBS in H2O, air-dried, and heat-fixed at 65°C for 8 h. Twofold serial
dilutions of duplicate serum samples were added to the plate,
followed by incubation with a peroxidase-labeled anti-ferret IgG
antiserum (1:750; Bethyl Laboratories Inc., Montgomery, USA).
Bound antibody was visualized using amino-ethyl-carbazole, and
antibody titers were expressed as the reciprocal value of the last
dilution with positive staining.
Microneutralization assay
Influenza MN assay was done in essence as described (He et al,
2015) with the exception that 3.5 × 104 PFU of influenza virus
was used per 96 well to examine mouse sera and 2 × 102 PFU per
96 well for ferret sera. Detection of influenza antigen was done
with anti-influenza A polyclonal antibody (1:1,000; 5315-0064;
Bio-Rad) and suited secondary antibody coupled to HRP (1:1,000;
Agilent Technologies). AAV MN was done as described (Meliani
et al, 2015) with the exception that AAV-GFP was used as reporter
virus and GFP-positive cells were quantified by flow cytometry in
a FACSCalibur cytometer (BD Biosciences). Percent inhibition was
calculated at each dilution step, and the MN50 (dilution step at
which 50% inhibition was measured) was determined using non-
linear fit of the inhibition curves [(Inhibitor) vs. response-variable
slope (four parameters)] in the GraphPad Prism software. The
limits of detection were dilutions of 1:100 (for AAV MN), 1:40
(for mouse influenza MN), and 1:10 (for ferret influenza MN),
respectively.
Hemagglutinin inhibition (HAI)
Animal sera were inactivated with trypsin-heat-KIO4 treatment
(WHO, 2002). Twofold dilutions of sera in PBS were prepared in
25 ll per 96-well. Four HAU per 25 ll PBS of influenza virus were
added to each well, and samples were incubated at 37°C for 1 h.
50 ll of 1% chicken red blood cells in PBS was added to each well,
and samples were incubated at 4°C for 20 min before agglutination
inhibition titers were determined as lowest serum dilution with a
clear agglutination clot. The limit of detection was a dilution of
1:40.
Epitope screen
Unmodified 15-mer peptides overlapping by five amino acids
(peptides & elephants GmbH, Hennigsdorf, Germany) were recon-
stituted in 50% DMSO in H2O. MaxiSorb ELISA plates (Thermo
Fischer Scientific) were coated with 1 lg of peptide in 50 ll
carbonate/bicarbonate buffer (pH = 9.6) per well overnight at
4°C. Plates were blocked 1 h at 37°C with 1% BSA in PBST1%
before mouse serum (1:200) in 50 ll blocking buffer was added
and plates were incubated at 37°C for 1 h. After washing, plates
were incubated with anti-mouse-IgG-HRP (1:500; Agilent Tech-
nologies) for 45 min at 37°C, before plates were washed again
and -StepTM Ultra TMB-ELISA Substrate Solution (Thermo Fischer
Scientific) was added for 10–20 min until color reaction was
stopped with 1 M H2SO4. Optical density was measured at
450 nm (OD450 nm). Values were normalized to negative control
serum (AAV-GFP).
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FccR assay
To display influenza virus surface antigens on MDCKII cells, cells were
seeded into 96-well plates and either infected with influenza virus
(3.5 × 103 PFU per well) or transfected with pAAV-HA or pAAV-mHL1
plasmids for 24 h using Lipofectamine 2000 (Thermo Fisher Scien-
tific). 50 ll of twofold serial serum dilutions in R10 medium was
added to each well at 37°C for 1 h. MDCKII cells were washed once
with PBS, before 2 × 105 of either BW:FccRI-f, BW:FccRIIB-f, BW:
FccRIII-f, or BW:FccRIV-f reporter cells were added per well in 200 ll
R10 medium, and plates were incubated at 37°C overnight. These
reporter cells express one of the four murine FccR (I, IIB, III, IV), which
was fused to the CD3-f transmembrane and signaling domain. Thus,
activation of the FccR by immune complexes triggers IL-2 production,
which is quantified by ELISA (Corrales-Aguilar et al, 2013; Van den
Hoecke et al, 2017). To release intracellular IL-2 cells were disrupted
by the addition of Tween 20 and resuspended. Supernatant was trans-
ferred to MaxisorbTM ELISA plates (Thermo Fischer Scientific), which
had been precoated with rat anti-mouse-IL2 capture antibody (1:500;
554424, BD Biosciences), and plates were left at RT for 1 h. After
washing, biotinylated-IL2 detection antibody (1:500; 554426, BD Bios-
ciences) was added and plates were incubated at RT for 1 h. After
washing again, streptavidin–HRP (1:1,000; 016-030-084, Jackson
ImmunoResearch, Ely, IK) was added at RT for 30 min before plates
were washed and 1-StepTM Ultra TMB-ELISA Substrate Solution
(Thermo Fischer Scientific) was added for 1–5 min before reaction
was stopped with 1 M H2SO4. Optical density was measured at
450 nm (OD450 nm).
Animal challenge studies
All mouse and ferret immunization and challenge experiments were
approved by the local committees and were conducted in
accordance with national guidelines for the care and use of labora-
tory animals (Landesamt für Gesundheit und Soziales (Berlin,
Germany) approval G0255/16, Regierungspräsidium Darmstadt
(Germany) approval F107/117 and IMI17 by Regierungspräsidium
Tübingen).
Handling of mice
Female 6- to 8-week-old C57BL/6 mice were purchased from
Charles River Laboratories (Sulzfeld, Germany) and housed at the
animal facility of the Robert Koch Institute (Berlin, Germany).
The minimally required animal numbers per group were deter-
mined using the software tool G*Power 3.1.6 (University of Kiel,
Germany) with data obtained in an initial immunization study
aiming at a power of 80%. Mice were anesthetized by isoflurane
inhalation, before 50 ll PBS containing 1011 vg of AAV vectors
was added dropwise to both nostrils. Mice were immunized three
times with AAV vectors in 3-week intervals. Likewise, 20 lg of
Cal/7/9 (X-181) in PBS was administered intranasally two times
with the first and the second immunization of the AAV vector-
vaccinated animals. Retro-orbital sinus blood samples were taken
from the animals before each and after the last immunization
from which serum was obtained for serological assays. Three
weeks after the third immunization, animals were challenged with
Cal/7/9 virus (7.94 × 103 TCID50/mouse, 500 MID50) or A/Puerto
Rico/8/1934 virus (2.51 × 104 (low dose) or 5.01 × 104 (high
dose) TCID50/mouse, 100 or 200 MID50) in 50 ll PBS. During
low-dose PR8 challenge, a single AAV-GFP-immunized animal,
which survived without weight loss, remained influenza virus
seronegative, indicating that the inoculum was not taken up prop-
erly during challenge infection. This animal was therefore
excluded from the analysis. Following infection, mice present-
ing ≥ 20% weight loss were anesthetized and euthanized by
isoflurane overdosing and lungs were harvested. Lungs of surviv-
ing mice were harvested on day 14 post-infection. Lungs were
homogenized using a Fastprep-24 tissue homogenizer (MP
Biomedicals, Santa Ana, USA) equipped with matrix D-lysing
matrix tubes for 40 s at 6 m/s. After clarification, 10-fold serial
dilutions of the homogenates were prepared, and plaque assay
was done on MDCKII cells.
Ferrets
Sixteen 4-month-old male ferrets (Mustela putorius furo) were
purchased from EuroFerret (Denmark) and housed at the animal
facilities of the Paul-Ehrlich-Institute (Langen, Germany) and
tested seronegative for circulating influenza viruses prior to the
experiment. Ferrets were anesthetized by intramuscular injection
of ketamine (100 mg/kg) and medetomidine (0.05 mg/kg), before
a total of 300 ll PBS containing 7.5 × 1012 vg of AAV vectors
were added dropwise to both nostrils. The anesthesia was then
reversed by subcutaneous injection of atipamezole (0.2 mg/kg).
Ferrets were immunized three times with AAV vectors in 4-week
intervals. One human dose per ferret of quadrivalent inactivated
influenza vaccine of season 2017/18 containing 15 lg HA per
vaccine component (Influsplit Tetra, GSK, Brenford, USA) was
given intramuscularly into the posterior limbs two times in
parallel with the first and the second AAV vector vaccine. Blood
The paper explained
Problem
Current seasonal influenza vaccines show low effectiveness and
protection is limited to the virus strains contained within the vaccine.
High morbidity and mortality caused by seasonal influenza and the
risk of emergence of pandemic and/or zoonotic virus strains empha-
size the urgent need for a broadly reactive vaccine.
Results
AAV vectors were used to deliver influenza antigens to the lung of
mice and ferrets to induce protective immunity. AAV vectors express-
ing HA, NP, or chimeric HA were shown to protect mice from chal-
lenge with divergent H1N1 virus strains. This was associated with the
induction of non-neutralizing but FccR-activating antibodies. AAV-HA
was also shown to induce protective immunity in ferrets against a
homologous H1N1 challenge.
Impact
The results of this work demonstrate that the AAV vectors are promis-
ing carriers for a broadly reactive influenza vaccine. The vectored
expression of the antigen was shown to balance the immune
response toward more conserved broadly reactive epitopes within the
influenza virus antigens and to induce high levels of FccR-activating
antibodies. Furthermore, the licensure of AAV vector for human gene
therapy could ease further clinical development of a vaccine.
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samples were collected before each and after the last immuniza-
tion from which serum was obtained for serological analysis.
Four weeks after the third immunization, animals were chal-
lenged intranasally with 1 × 105 TCID50 of A/Mexico/InDre4487/
2009 (H1N1)pdm in 200 ll Opti-MEM.
Ferrets were monitored daily for signs of disease using a 0-1-2
scale for each activity (normal, calm, depressed), respiratory signs
(sneezing, nose exudate, and congestion), and general clinical signs.
Zero indicates minimal deviation from the physiological state, 1
indicates moderate nasal discharge, congestion, and/or occasional
sneezing and/or calm temper, while 2 indicates severe nasal
discharge and/or labored breathing, dyspnea, and frequent sneezing
and/or depressed manner (Walz et al, 2018). Final clinical scores
were calculated by summation of activity, respiratory signs, and
general clinical sign records per ferret per time point. Changes in
body weight and body temperature were measured. On day 3 post-
infection, animals were anesthetized by injection of ketamine
(100 mg/kg) and medetomidine (0.05 mg/kg), exsanguinated, and
nasal turbinates, trachea and lung were harvested. Nasal turbinates
and samples of the trachea and the lung were homogenized, and
virus titers were determined by TCID50 assay as described before
(Walz et al, 2018). Lung samples were immersion-fixed in formalin
for histopathological examination.
Lung histopathology and immunohistochemistry
Formalin-fixed trachea and lung samples were embedded in paraf-
fin, cut in 2-lm sections, and stained with hematoxylin and eosin
(H&E) after dewaxing in xylene and rehydration in decreasing etha-
nols. Lung sections were microscopically evaluated by board-
certified veterinary pathologists (KD, ADG) in a blinded fashion to
assess character and severity of pathologic lesions using lung-
specific inflammation score parameters for quantifying influenza
virus-induced pneumonia as described (Dietert et al, 2017). These
parameters included severity of (i) interstitial pneumonia with infil-
tration by macrophages, lymphocytes, neutrophils (ii) bronchitis,
(iii) epithelial necrosis of bronchi, alveoli, and submucosal glands,
(iv) perivascular lymphocytic cuffing, and (v) hyperplasia of type II
pneumocytes.
For immunohistochemical detection of influenza A virus,
heat-mediated antigen retrieval was performed in 10 mM of citric
acid (pH = 6.0), in which samples were microwaved at 600 W
for 12 min. Lung sections were incubated with a polyclonal
influenza A H1N1 antibody (1:250; 5315-0064, AbD Serotec,
Puchheim, Germany) at 4°C overnight. Incubation with an irrele-
vant antibody at the same dilution served as negative control.
Subsequently, slides were incubated with a suited secondary,
phosphatase-conjugated antibody (1:500; AP-1000, Vector, Burlin-
game, CA, USA) for 30 min at room temperature. Afterward,
triamino-tritolyl-methanechloride (Neufuchsin) was added to the
slides, yielding a reddish stain upon processing by the phos-
phatase. Slides were counterstained with hematoxylin, dehy-
drated through graded ethanols, cleared in xylene, and cover-
slipped. Samples from non-influenza infected ferrets served as
negative control for histopathological and immunohistochemical
analysis. Neither one of the above-mentioned influenza infection-
specific parameter nor influenza virus antigen could be detected
in these control samples.
Statistical analyses
Statistical analysis and plotting of data were performed with
GraphPad Prism Version 7.04. Statistical significance between
unpaired groups was analyzed using Kruskal–Wallis test with
Dunn’s post-testing as indicated in the figure legends. Statistical
significance between two unpaired groups was analyzed using
Mann–Whitney test as indicated in the figure legends. Statistical
significance between two paired groups was analyzed using
Wilcoxon paired. Differences between time points were analyzed
with Friedman test with Dunn’s post-testing as indicated in the fig-
ure legends. Statistically significant differences between survival
curves were calculated with log-rank (Mantel–Cox) test. Linear
regression analysis was performed with default settings in
GraphPad.
Expanded View for this article is available online.
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